alexa
Reach Us +441414719275
Editor - Halmuthur Kumar | Gulbarga University , India | 23284
ISSN: 2376-0427

Dermatology and Dermatologic Diseases
Open Access

Like us on:

Previously: Journal of Pigmentary Disorders

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Relevant Topics

Halmuthur Kumar

Halmuthur M Sampath Kumar
Indian Institute of Chemical Technology,
Hyderabad, India

Biography

Halmuthur M Sampath Kumar, obtained his MSc (chemistry) from Gulbarga University and PhD from Indian Institute of Chemical Technology, Hyderabad (1995) in the area of biomimetic chemistry. He later moved to Max Planck Institute of Dortmund 2000 as Humboldt Fellow to work with Prof. Waldmann in the area of gene therapy. After returning to CSIR-IICT , he worked on agrochemical and pharmaceutical technology development. Subsequently he relocated to Regional Research Laboratory(2004)-Jammu, presently rechristened as IIIM-Jammu where, he initiated major projects on cosmeceuticals. His team developed novel skin care hybrid molecules and worked on major collaboarative projects with P&G and Colgate Plamolive on oral and skin care product development. He served as the chairman of the Biological Chemistry department till 2009. Currently he is the nodal scientist for the vaccine immunology programme at IICT-Hyderabad.

Research Interest

development of minimum cosmeceuticals employing hybrid technologies, novel small molecule immunomodulators, vaccine(Th1) adjuvants

Top